Avid Bioservices (NASDAQ:CDMO – Get Free Report) had its target price raised by Royal Bank of Canada from $7.00 to $8.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 3.90% from […]
Avid Bioservices (NASDAQ:CDMO – Get Free Report) had its price objective raised by equities researchers at Royal Bank of Canada from $7.00 to $8.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target suggests a potential […]
Avid Bioservices, Inc. (NASDAQ:CDMO – Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 5,230,000 shares, a decrease of 5.6% from the January 15th total of 5,540,000 shares. Based on an average daily volume of 1,450,000 shares, […]